We've found
6,847 Skin Cancer
clinical trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Melanoma Clinical Trial
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Status: Enrolling,
Phase
III
Updated: 8/10/2016
Click here to add this to my saved trials
Melanoma Clinical Trial
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Status: Enrolling,
Phase
III
Updated: 8/10/2016
Click here to add this to my saved trials
Melanoma Clinical Trial
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Status: Enrolling,
Phase
III
Updated: 8/10/2016
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Habouring NTRK Fusion Clinical Trial
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Desmoplastic Melanoma Clinical Trial
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Desmoplastic Melanoma Clinical Trial
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Desmoplastic Melanoma Clinical Trial
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Melanoma Clinical Trial
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Melanoma Clinical Trial
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Melanoma Clinical Trial
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Stage III/IV Melanoma Clinical Trial
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
6,847 Skin Cancer
clinical trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Melanoma Clinical Trial
Updated: 8/10/2016
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Status: Enrolling,
Phase
III
Updated: 8/10/2016
Click here to add this to my saved trials
Melanoma Clinical Trial
Updated: 8/10/2016
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Status: Enrolling,
Phase
III
Updated: 8/10/2016
Click here to add this to my saved trials
Melanoma Clinical Trial
Updated: 8/10/2016
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Status: Enrolling,
Phase
III
Updated: 8/10/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Habouring NTRK Fusion Clinical Trial
Updated: 12/31/1969
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Desmoplastic Melanoma Clinical Trial
Updated: 12/31/1969
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Desmoplastic Melanoma Clinical Trial
Updated: 12/31/1969
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Desmoplastic Melanoma Clinical Trial
Updated: 12/31/1969
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial
Updated: 12/31/1969
Registry Study for Talimogene Laherparepvec
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Melanoma Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
Updated: 12/31/1969
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
Updated: 12/31/1969
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
Updated: 12/31/1969
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced BRAFV600 Wild-type Melanoma Clinical Trial
Updated: 12/31/1969
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Melanoma Clinical Trial
Updated: 12/31/1969
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Melanoma Clinical Trial
Updated: 12/31/1969
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Stage III/IV Melanoma Clinical Trial
Updated: 12/31/1969
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials